In partnership with
COMPENSATION
Hitting Quota. Still Feeling Underpaid.
We just released the newest 2026 Medical Device Sales Compensation Report.
One number immediately stood out:
104%
That’s the median quota attainment among respondents who said they do not feel fairly compensated.
For reps who said they do feel fairly compensated?
105%.
Virtually identical.
And that wasn’t the only disconnect.
51% of respondents reported $200K+ in total W-2 compensation.
36% reported $300K+.
20% reported $400K+.
And 80% of respondents reporting quota attainment were at or above plan.
Yet only 48% of respondents answering the fairness question said they feel fairly compensated.
So what’s going on?
The open-ended responses provide a clue.
The largest source of frustration wasn’t raw pay.
Quota and compensation-plan design accounted for 34% of categorized frustrations.
One respondent put it simply:
“Comp plan is always changing. More tenured reps always getting crushed by quota increases.”
Medical device sales can still be an incredibly lucrative career.
But high pay and fair pay aren’t necessarily the same thing.
If a rep grows a territory 20%, gets rewarded with a significantly larger quota, and has to grow another 15% just to make the same money next year, the W-2 only tells part of the story.
That’s something we’re going to keep tracking as the MDR Compensation Index grows.
Anonymous self-reported data. Results are directional and not a randomized sample of the U.S. medical device sales workforce.
HITTING QUOTA ≠ FEELING FAIRLY PAID
104%
Median quota attainment among reps who say they feel underpaid
105% FAIRLY PAID | 104% UNDERPAID
Source: MDR Compensation Index, Sept. 2026
CAREERS
Your Sales Background Won’t Save You in the OR
This week, The Med Device Rep sat down with orthopedic foot and ankle surgeon Dr. Selene Parekh.
One of his stories should get the attention of anyone trying to break into medical device sales.
A new rep showed up in his OR after being hired from Starbucks.
There is nothing inherently wrong with coming from outside medical device.
Everyone starts somewhere.
The problem?
The rep didn’t know the product or the procedure.
Parekh’s response was simple:
The rep wasn’t allowed back in his room.
It’s a harsh example, but it highlights something candidates often misunderstand about breaking into this industry.
Getting hired is only the beginning.
You can interview well.
You can be charismatic.
You can have a strong sales track record.
But once you’re standing in an operating room, none of that substitutes for knowing what you’re doing.
Surgeons and staff need to trust that the person representing the product understands the product.
And preferably understands the procedure well enough to anticipate what comes next.
That’s why onboarding and training matter.
It’s also why the responsibility doesn’t end with the company.
If you’re the person walking into that room, you own your preparation.
We asked Dr. Parekh a lot more.
Including blind ranking the five most important traits he looks for in a medical device rep and telling us what he thinks reps need to stop doing in the OR.
We’ll be releasing the conversation in several short clips beginning this week.
ORTHOPEDIC SURGEON DR. SELENE PAREKH
What makes a great medical device rep?
New MDR Interview Series
Sponsored by MarketBeat:
The 10 Best AI Stocks to Own in 2026
AI is moving from experiment… to essential.
Every major industry is integrating it.
Every major company is investing in it.
By late 2025, AI was already an $800B market — growing at a pace that could push it well beyond $1 trillion in the years ahead.
Cloud infrastructure is scaling fast.
AI-enabled devices are multiplying.
Automation is becoming standard.
But here’s the real question…
When trillions flow into this transformation — which stocks stand to benefit most?
Our new report reveals 10 AI stocks positioned across the backbone of this shift — from the companies powering the infrastructure… to those embedding intelligence into everyday systems.
If you want exposure to one of the defining growth trends of this decade, start here.
INDUSTRY
Could DePuy Synthes Become a $20 Billion Private Equity Company?
This could be one of the biggest medtech transactions in years.
Apollo Global Management is reportedly in talks to acquire DePuy Synthes, Johnson & Johnson’s orthopedic business, in a deal that could value it near $20 billion.
No deal has been announced, and J&J could still pursue a spinout or another option.
But with DePuy Synthes generating approximately $9.3 billion in 2025 revenue, a change of ownership at this scale would have major implications across orthopedics.
What should reps watch?
The commercial organization.
Territories, leadership, distributor relationships, quotas and compensation plans could eventually come into play.
Where the investment goes.
Orthopedics is increasingly a battle over robotics, navigation, data and integrated surgical ecosystems, not just implants.
The portfolio.
New ownership could change where capital gets deployed and which parts of the massive DePuy portfolio receive the most attention.
None of those changes have been announced. But if this deal happens, the implications will extend far beyond DePuy.
For reps across orthopedics, this is one to watch.
THE $20 BILLION QUESTION
JOHNSON & JOHNSON
↓
DEPUY SYNTHES
↓
APOLLO?
Potential valuation: ~$20B
ONE MORE THING
The Compensation Index gets more useful with every submission.
We’re working toward something the medical device industry has never had:
Transparent compensation benchmarks by role, specialty, experience and eventually company.
We’re not there yet.
We need more data.
If you work in medical device sales, add yours.
100% anonymous. No email required. Under 3 minutes.
See you next week.
The Med Device Rep
The independent source for medical device sales.
Compensation. Careers. Industry.
The Med Device Rep
TheMedDeviceRep.com